Following the successful online sessions held during the first three days of the CGOG Annual Meeting, including six ASCO Highlights sessions and six thematic symposia, the on-site program officially commenced on June 12. On Day 4 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting, two parallel forums attracted strong interest from attendees. The Precision Translational Medicine Forum brought together experts from a wide range of academic disciplines for in-depth exchange and discussion.

Following the successful completion of six ASCO Highlights sessions and six thematic symposia during the first three days of the CGOG Annual Meeting, the conference transitioned to its in-person program…

The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.

In the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, the choice of chemotherapy regimen, timing of administration (neoadjuvant vs. adjuvant), and optimization of dose density remain focal points of clinical debate for biologically high-risk patients. In a recent academic conference, Professor Oleg Gluz from the West German Study Group (WSG) shared pooled analysis data from the WSG ADAPT-HR+/HER2- and PlanB studies. This analysis focused on a high-risk population with a Recurrence Score (RS) >25 or lymph node positivity (>4), aiming to explore the impact of different chemotherapy strategies on long-term patient survival.

At the recent 2026 ASCO Annual Meeting, Professor Peter Schmid, representing the lidERA study group from the Barts Cancer Institute, Queen Mary University of London, detailed the efficacy and safety analysis results based on menopausal status (pre/perimenopausal vs. postmenopausal) from the Phase III lidERA BC clinical trial. The study aims to evaluate the clinical value of Giredestrant (GIRE), a next-generation oral selective estrogen receptor degrader (SERD), in the adjuvant treatment of patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer (eBC).

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on the efficacy of Sacituzumab Govitecan (SG) combined with Pembrolizumab as a first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC), providing key evidence for the precise selection of benefited populations in clinical practice.

The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.

The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.

At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following therapeutic or prophylactic mastectomy.

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.